Review of over 15 years post-marketing safety surveillance spontaneous data for the human rotavirus vaccine (*Rotarix*) on intussusception

Journal: Drug Safety

Authorship: Tina Singh[1], Frédérique Delannois[1], François Haguinet[1], Lifeter Yenwo Molo[1]

Affiliations:

[1]GSK, Avenue Fleming 20, 1300 Wavre, Belgium

Corresponding author:

Tina Singh

tina.x.singh@gsk.com

Electronic supplementary material 10 Significance area for the equality test of observed and expected incidences within (a) 30 days (day 0–day 29) and (b) 7 days (day 0–day 6) after the first dose, and within (c) 30 days (day 0–day 29) and (d) 7 days (day 0–day 6) after any dose according to the reported fraction of events, United States


a
b
c
d
Low Ref.
Number of cases
Reported fraction (RF)
0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
BCL1
BCL3
BCL4
Expected
95%CI

BCL1, Brighton Collaboration Working Group level 1; BCL3, Brighton Collaboration Working Group levels 1–3; BCL4, Brighton Collaboration Working Group levels 1–4; Low Ref. – High Ref., range of expected cases according to background incidence rates (high ref is out of scale on all panels); 95% CI, 95 percent confidence interval. Total number of doses was 10,945,330 for panels a and b (after first dose) and 21,890,660 for panels c and d (after any dose).